Immuno Oncology Market Scope
Immuno-oncology therapy can provide more durable clinical outcomes than traditional therapies such as chemotherapy and radiotherapy and in some cases contribute to complete tumor regression. Immuno-oncology therapies also pose a less detrimental impact on patientsí quality of life due to a lower incidence of serious adverse events. Moreover, the rising number of cancer cases worldwide is one of the major factors aiding the growth of the market. Amid the lockdown across different regions, patients suffering from cancer were expected to be at a higher risk, due to the COVID-19 which has also made it difficult to manage the cancer care delivery system. So the requirement of oncologists to be more attentive to detect coronavirus infection early, as any type of advanced cancer is at much higher risk for unfavorable outcomes for the patients. Moreover, due to the lockdown across different countries, the patients were not able to travel from one place to another for their treatment which has led to a slight disparity in cancer care across different regions. Therefore, the global immuno-oncology market is expected to witness a slight decline in its y-o-y growth during the FY-2020 compared to FY 2019 which is again expected to regain its positive growth in FY 2021.
The Immuno Oncology market study is segmented and major geographies with country level break-up.
The Players having a strong hold in the market are F. Hoffmann-La Roche Ltd. Merck & Co., Inc Bristol-Myers Squibb Company Novartis AG Pfizer Inc.. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Immuno Oncology market throughout the predicted period.
Amgen Inc. (United States), AstraZeneca (United Kingdom), Bristol Myers Squibb (United States), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Incyte (United States) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Eli Lilly and Company (United States), Johnson & Johnson Services, Inc. (United States), AbbVie Inc. (United States), Gilead Sciences, Inc. (United States), Aduro Biotech Inc. (United States), SELLAS Life Sciences Group Ltd (United States), Celldex Therapeutics (United States) and BeiGene (China).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Immuno Oncology market by Type, Application and Region. On the basis of Type, Checkpoint Inhibitors & Immunomodulators are dominating the market in the year 2019 where as Cancer Vaccines stood as second largest market share.
On the basis of application, Hospitals segment is dominating the market in the year 2019
On the basis of geography, the market of Immuno Oncology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). NA region held largest market share in the year 2019. Asia Pacific on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.
Market Leaders and their expansionary development strategies
In September 2020, AstraZeneca has entered into an agreement with Dogma Therapeutics to acquire its preclinical oral PCSK9 inhibitor programme. With this acquisition, it aims to take the programme forward into clinical development for dyslipidaemia, or abnormal amount of lipids in the blood, and familial hypercholesterolemia, a common genetic condition that causes high cholesterol
In January 2020, Pfizer Inc. announced the launch of its Vaccines Divisionís Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults.
FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins and some nucleic acids.
- Technological Advancement Propelled by Adoption of Next Generation Cancer Treatment
- Growing Incidence of Cancer Across the World
- Growing Healthcare Infrastructure Across Developing Regions
- Rising Investments in Development of Cancer Drugs & Treatment
- Challenges in Immuno-Oncology Trials
Key Target Audience
Laboratories & Research Institutes, Pharmaceutical Companies, End-Use Industries and Others
Frequently asked questions:1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.2. How big is the Immuno Oncology Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2025.3. What is expected growth rate?
According to AMA, the Global Immuno Oncology market is expected to see growth rate of 13.81%.